Graft-Versus-Host Disease

  • Edgar M. Espana
  • Lauren Jeang
  • Arun D. Singh


Graft-versus-host disease (GVHD) is a serious and devastating complication following bone marrow transplantation. Acute or chronic systemic GVHD can be lethal, and severe damage of different organs and tissues occurs with both types of GVHD. Ocular involvement, either in an acute or chronic presentation, may range from mild to severe. Chronic ocular GVHD, the most common form of GVHD, affects mainly the ocular surface components: lacrimal gland, meibomian glands, cornea, and conjunctiva, mimicking other immunologically mediated inflammatory diseases of the ocular surface. The long-term treatment of ocular GVHD continues to be challenging and involves a multidisciplinary approach where medical and surgical options are necessary. Systemic immunosuppression, ocular lubricants, topical steroids, and topical cyclosporine are commonly prescribed. More aggressive therapeutic interventions for moderate and severe ocular GVHD include the use of serum eye drops and scleral contact lenses. In this chapter, we review the mechanisms, clinical findings, and treatment of ocular GVHD.


GVHD Sicca Dry eyes Serum eye drops Scleral lenses Immunosuppression 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813–26.CrossRefGoogle Scholar
  2. 2.
    Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61.Google Scholar
  3. 3.
    de la Morena MT, Gatti RA. A history of bone marrow transplantation. Immunol Allergy Clin North Am. 2010;30(1):1–15.CrossRefGoogle Scholar
  4. 4.
    Chen YB, Kawai T, Spitzer TR. Combined bone marrow and kidney transplantation for the induction of specific tolerance. Adv Hematol. 2016;2016:6471901.CrossRefGoogle Scholar
  5. 5.
    Mancardi G, Sormani MP, Muraro PA, et al. Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis. Mult Scler. 2018;24(3):245–55.CrossRefGoogle Scholar
  6. 6.
    Niederwieser D, Baldomero H, Szer J, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016;51(6):778–85.CrossRefGoogle Scholar
  7. 7.
    Choi SW, Levine JE, Ferrara JL. Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am. 2010;30(1):75–101.CrossRefGoogle Scholar
  8. 8.
    Thomas ED, Lochte HL Jr, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257(11):491–6.Google Scholar
  9. 9.
    Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966;62:21–78.PubMedGoogle Scholar
  10. 10.
    Kernan NA, Collins NH, Juliano L, et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood. 1986;68(3):770–3.PubMedGoogle Scholar
  11. 11.
    Loiseau P, Busson M, Balere ML, et al. HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant. 2007;13(8):965–74.CrossRefGoogle Scholar
  12. 12.
    Zeiser R, Blazar BR. Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. N Engl J Med. 2017;377(26):2565–79.CrossRefGoogle Scholar
  13. 13.
    Pidala J, Anasetti C, Kharfan-Dabaja MA, et al. Decision analysis of peripheral blood versus bone marrow hematopoietic stem cells for allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15(11):1415–21.CrossRefGoogle Scholar
  14. 14.
    Barker JN, Krepski TP, DeFor TE, et al. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant. 2002;8(5):257–60.CrossRefGoogle Scholar
  15. 15.
    Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood. 2002;100(5):1611–8.PubMedGoogle Scholar
  16. 16.
    Platzbecker U, Ehninger G, Bornhauser M. Allogeneic transplantation of CD34+ selected hematopoietic cells – clinical problems and current challenges. Leuk Lymphoma. 2004;45(3):447–53.CrossRefGoogle Scholar
  17. 17.
    Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(2):211–34.CrossRefGoogle Scholar
  18. 18.
    Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56.CrossRefGoogle Scholar
  19. 19.
    Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1.CrossRefGoogle Scholar
  20. 20.
    Ram R, Gafter-Gvili A, Yeshurun M, et al. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant. 2009;43(8):643–53.CrossRefGoogle Scholar
  21. 21.
    Sale GE. Does graft-versus-host disease attack epithelial stem cells? Mol Med Today. 1996;2(3):114–9.CrossRefGoogle Scholar
  22. 22.
    Socie G, Blazar BR. Acute graft-versus-host disease: from the bench to the bedside. Blood. 2009;114(20):4327–36.CrossRefGoogle Scholar
  23. 23.
    Jabs DA, Hirst LW, Green WR, et al. The eye in bone marrow transplantation. II. Histopathology. Arch Ophthalmol. 1983;101(4):585–90.CrossRefGoogle Scholar
  24. 24.
    Hirst LW, Jabs DA, Tutschka PJ, et al. The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol. 1983;101(4):580–4.CrossRefGoogle Scholar
  25. 25.
    Ogawa Y, Kuwana M. Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation. Cornea. 2003;22(7 Suppl):S19–27.CrossRefGoogle Scholar
  26. 26.
    Ogawa Y, Kodama H, Kameyama K, et al. Donor fibroblast chimerism in the pathogenic fibrotic lesion of human chronic graft-versus-host disease. Invest Ophthalmol Vis Sci. 2005;46(12):4519–27.CrossRefGoogle Scholar
  27. 27.
    Kim SK. Ocular graft vs. host disease. Ocul Surf. 2005;3(4 Suppl):S177–9.PubMedGoogle Scholar
  28. 28.
    Espana EM, Shah S, Santhiago MR, et al. Graft versus host disease: clinical evaluation, diagnosis and management. Graefes Arch Clin Exp Ophthalmol. 2013;251(5):1257–66.Google Scholar
  29. 29.
    Westeneng AC, Hettinga Y, Lokhorst H, et al. Ocular graft-versus-host disease after allogeneic stem cell transplantation. Cornea. 2010;29(7):758–63.CrossRefGoogle Scholar
  30. 30.
    Blecha C, Wolff D, Holler B, et al. Verification of the new grading scale for ocular chronic graft-versus-host disease developed by the German-Austrian-Swiss consensus conference on chronic GVHD. Ann Hematol. 2016;95(3):493–9.CrossRefGoogle Scholar
  31. 31.
    Riemens A, te Boome L, Imhof S, et al. Current insights into ocular graft-versus-host disease. Curr Opin Ophthalmol. 2010;21(6):485–94.CrossRefGoogle Scholar
  32. 32.
    Ban Y, Ogawa Y, Ibrahim OM, et al. Morphologic evaluation of meibomian glands in chronic graft-versus-host disease using in vivo laser confocal microscopy. Mol Vis. 2011;17:2533–43.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Tabbara KF, Al-Ghamdi A, Al-Mohareb F, et al. Ocular findings after allogeneic hematopoietic stem cell transplantation. Ophthalmology. 2009;116(9):1624–9.CrossRefGoogle Scholar
  34. 34.
    Koch KR, Joussen AM, Huber KK. Ocular involvement in chronic graft-versus-host disease: therapeutic approaches to complicated courses. Cornea. 2011;30(1):107–13.CrossRefGoogle Scholar
  35. 35.
    He J, Ogawa Y, Mukai S, et al. In vivo confocal microscopy evaluation of ocular surface with graft-versus-host disease-related dry eye disease. Sci Rep. 2017;7(1):10720.CrossRefGoogle Scholar
  36. 36.
    Inamoto Y, Chai X, Kurland BF, et al. Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology. 2012;119(3):487–93.CrossRefGoogle Scholar
  37. 37.
    Shah A, Santhiago MR, Espana EM. Cataract surgery in patients with chronic severe graft-versus-host disease. J Cataract Refract Surg. 2016;42(6):833–9.CrossRefGoogle Scholar
  38. 38.
    Tung CI. Graft versus host disease: what should the oculoplastic surgeon know? Curr Opin Ophthalmol. 2017;28(5):499–504.CrossRefGoogle Scholar
  39. 39.
    Cocho L, Fernandez I, Calonge M, et al. Biomarkers in ocular chronic graft versus host disease: tear cytokine- and chemokine-based predictive model. Invest Ophthalmol Vis Sci. 2016;57(2):746–58.CrossRefGoogle Scholar
  40. 40.
    Wolff D, Schleuning M, von Harsdorf S, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(1):1–17.CrossRefGoogle Scholar
  41. 41.
    Savini G, Prabhawasat P, Kojima T, et al. The challenge of dry eye diagnosis. Clin Ophthalmol. 2008;2(1):31–55.CrossRefGoogle Scholar
  42. 42.
    Robinson MR, Lee SS, Rubin BI, et al. Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant. 2004;33(10):1031–5.CrossRefGoogle Scholar
  43. 43.
    Yin J, Kheirkhah A, Dohlman T, et al. Reduced efficacy of low-dose topical steroids in dry eye disease associated with graft-versus-host disease. Am J Ophthalmol. 2018. pii: S0002-9394(18)30125-9.Google Scholar
  44. 44.
    Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321–38.CrossRefGoogle Scholar
  45. 45.
    Lelli GJ Jr, Musch DC, Gupta A, et al. Ophthalmic cyclosporine use in ocular GVHD. Cornea. 2006;25(6):635–8.CrossRefGoogle Scholar
  46. 46.
    Malta JB, Soong HK, Shtein RM, et al. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea. 2010;29(12):1392–6.CrossRefGoogle Scholar
  47. 47.
    Simpson D. Drug therapy for acute graft-versus-host disease prophylaxis. J Hematother Stem Cell Res. 2000;9(3):317–25.CrossRefGoogle Scholar
  48. 48.
    Ogawa Y, Okamoto S, Kuwana M, et al. Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea. 2001;20(4):430–4.CrossRefGoogle Scholar
  49. 49.
    Tam PM, Young AL, Cheng LL, et al. Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. Bone Marrow Transplant. 2010;45(5):957–8.Google Scholar
  50. 50.
    Rocha EM, Pelegrino FS, de Paiva CS, et al. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant. 2000;25(10):1101–3.CrossRefGoogle Scholar
  51. 51.
    Ogawa Y, Okamoto S, Mori T, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant. 2003;31(7):579–83.CrossRefGoogle Scholar
  52. 52.
    Inamoto Y, Sun YC, Flowers ME, et al. Bandage soft contact lenses for ocular graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(11):2002–7.CrossRefGoogle Scholar
  53. 53.
    Takahide K, Parker PM, Wu M, et al. Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2007;13(9):1016–21.CrossRefGoogle Scholar
  54. 54.
    DeLoss KS, Le HG, Gire A, et al. PROSE treatment for ocular chronic graft-versus-host disease as a clinical network expands. Eye Contact Lens. 2016;42(4):262–6.CrossRefGoogle Scholar
  55. 55.
    Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea. 2007;26(10):1195–9.CrossRefGoogle Scholar
  56. 56.
    Schornack MM, Baratz KH, Patel SV, et al. Jupiter scleral lenses in the management of chronic graft versus host disease. Eye Contact Lens. 2008;34(6):302–5.Google Scholar
  57. 57.
    Magro L, Gauthier J, Richet M, et al. Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC. Bone Marrow Transplant. 2017;52(6):878–82.CrossRefGoogle Scholar
  58. 58.
    Benyunes MC, Sullivan KM, Deeg HJ, et al. Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys. 1995;32(3):661–70.CrossRefGoogle Scholar
  59. 59.
    Dunn JP, Jabs DA, Wingard J, et al. Bone marrow transplantation and cataract development. Arch Ophthalmol. 1993;111(10):1367–73.CrossRefGoogle Scholar
  60. 60.
    Allan EJ, Flowers ME, Lin MP, et al. Visual acuity and anterior segment findings in chronic graft-versus-host disease. Cornea. 2011;30(12):1392–7.CrossRefGoogle Scholar
  61. 61.
    Saboo US, Amparo F, Shikari H, et al. Outcomes of phacoemulsification in patients with chronic ocular graft-versus-host disease. Graefes Arch Clin Exp Ophthalmol. 2015;253(6):901–7.CrossRefGoogle Scholar
  62. 62.
    Balaram M, Dana MR. Phacoemulsification in patients after allogeneic bone marrow transplantation. Ophthalmology. 2001;108(9):1682–7.CrossRefGoogle Scholar
  63. 63.
    Penn EA, Soong HK. Cataract surgery in allogeneic bone marrow transplant recipients with graft-versus-host disease(1). J Cataract Refract Surg. 2002;28(3):417–20.CrossRefGoogle Scholar
  64. 64.
    de Melo FR, Kron-Gray MM, De la Parra-Colin P, et al. Outcomes of cataract surgery in graft-versus-host disease. Cornea. 2015;34(5):506–11.CrossRefGoogle Scholar
  65. 65.
    Arai S, Jagasia M, Storer B, et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood. 2011;118(15):4242–9.CrossRefGoogle Scholar
  66. 66.
    de la Parra-Colin P, Agahan AL, Perez-Simon JA, et al. Dry eye disease in chronic graft-versus-host disease: results from a Spanish retrospective cohort study. Transplant Proc. 2011;43(5):1934–8.CrossRefGoogle Scholar
  67. 67.
    Ogawa Y, Okamoto S, Wakui M, et al. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol. 1999;83(10):1125–30.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Edgar M. Espana
    • 1
  • Lauren Jeang
    • 2
  • Arun D. Singh
    • 3
  1. 1.Department of OphthalmologyUniversity of South FloridaTampaUSA
  2. 2.Department of OphthalmologyNew England Eye Center/Tufts Medical CenterBostonUSA
  3. 3.Department of Ophthalmic OncologyCole Eye Institute, Cleveland ClinicClevelandUSA

Personalised recommendations